CY1123699T1 - Συστηματα προσθετων για χρηση σε ρεgυλιωση πρωτεϊνων - Google Patents
Συστηματα προσθετων για χρηση σε ρεgυλιωση πρωτεϊνωνInfo
- Publication number
- CY1123699T1 CY1123699T1 CY20201101102T CY201101102T CY1123699T1 CY 1123699 T1 CY1123699 T1 CY 1123699T1 CY 20201101102 T CY20201101102 T CY 20201101102T CY 201101102 T CY201101102 T CY 201101102T CY 1123699 T1 CY1123699 T1 CY 1123699T1
- Authority
- CY
- Cyprus
- Prior art keywords
- additive
- aminooxy
- solution
- additives
- combination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258644P | 2015-11-23 | 2015-11-23 | |
| PCT/US2016/063313 WO2017091568A1 (en) | 2015-11-23 | 2016-11-22 | Additive systems for use in protein pegylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123699T1 true CY1123699T1 (el) | 2022-03-24 |
Family
ID=57589163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201101102T CY1123699T1 (el) | 2015-11-23 | 2020-11-20 | Συστηματα προσθετων για χρηση σε ρεgυλιωση πρωτεϊνων |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10617765B2 (enExample) |
| EP (2) | EP3789395B1 (enExample) |
| JP (2) | JP6921821B2 (enExample) |
| KR (1) | KR102688003B1 (enExample) |
| CN (2) | CN108350025B (enExample) |
| CY (1) | CY1123699T1 (enExample) |
| DK (1) | DK3380487T3 (enExample) |
| ES (1) | ES2827776T3 (enExample) |
| HR (1) | HRP20201832T1 (enExample) |
| HU (1) | HUE052634T2 (enExample) |
| LT (1) | LT3380487T (enExample) |
| PL (1) | PL3380487T3 (enExample) |
| PT (1) | PT3380487T (enExample) |
| RS (1) | RS61072B1 (enExample) |
| SI (1) | SI3380487T1 (enExample) |
| SM (1) | SMT202000649T1 (enExample) |
| WO (1) | WO2017091568A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017091568A1 (en) * | 2015-11-23 | 2017-06-01 | Bristol-Myers Squibb Company | Additive systems for use in protein pegylation |
| LT3849614T (lt) * | 2018-09-11 | 2024-03-25 | Ambrx, Inc. | Interleukino-2 polipeptido konjugatai ir jų panaudojimas |
| CN111484551B (zh) * | 2020-03-19 | 2022-02-11 | 北京翼方生物科技有限责任公司 | 一种聚乙二醇修饰的重组人碱性成纤维细胞生长因子 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
| TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
| DE19734293A1 (de) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
| JP5460958B2 (ja) * | 2004-03-17 | 2014-04-02 | アンチキャンサー インコーポレーテッド | タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法 |
| TW200722521A (en) * | 2005-06-01 | 2007-06-16 | Alza Corp | Novel bioconjugation reactions for acylating polyethylene glycol reagents |
| JP5508716B2 (ja) * | 2005-11-08 | 2014-06-04 | アンブルックス，インコーポレイテッド | 非天然アミノ酸、および非天然アミノ酸ポリペプチドを修飾するための促進剤 |
| ES2385114T3 (es) * | 2007-03-30 | 2012-07-18 | Ambrx, Inc. | Polipéptidos de FGF-21 modificados y sus usos |
| CA2899448C (en) | 2013-01-30 | 2021-10-26 | Avelas Biosciences, Inc. | Selective delivery molecules and methods of use |
| HK1222122A1 (zh) | 2013-04-22 | 2017-06-23 | Avelas Biosciences, Inc. | 选择性药物递送组合物及使用方法 |
| SG11201702824UA (en) | 2014-10-24 | 2017-05-30 | Bristol Myers Squibb Co | Modified fgf-21 polypeptides and uses thereof |
| WO2017091568A1 (en) * | 2015-11-23 | 2017-06-01 | Bristol-Myers Squibb Company | Additive systems for use in protein pegylation |
-
2016
- 2016-11-22 WO PCT/US2016/063313 patent/WO2017091568A1/en not_active Ceased
- 2016-11-22 ES ES16816042T patent/ES2827776T3/es active Active
- 2016-11-22 PL PL16816042T patent/PL3380487T3/pl unknown
- 2016-11-22 DK DK16816042.2T patent/DK3380487T3/da active
- 2016-11-22 US US15/776,923 patent/US10617765B2/en active Active
- 2016-11-22 RS RS20201382A patent/RS61072B1/sr unknown
- 2016-11-22 EP EP20189107.4A patent/EP3789395B1/en active Active
- 2016-11-22 KR KR1020187017508A patent/KR102688003B1/ko active Active
- 2016-11-22 HR HRP20201832TT patent/HRP20201832T1/hr unknown
- 2016-11-22 HU HUE16816042A patent/HUE052634T2/hu unknown
- 2016-11-22 PT PT168160422T patent/PT3380487T/pt unknown
- 2016-11-22 SI SI201630957T patent/SI3380487T1/sl unknown
- 2016-11-22 CN CN201680067897.7A patent/CN108350025B/zh active Active
- 2016-11-22 CN CN202211743414.4A patent/CN115819494A/zh active Pending
- 2016-11-22 LT LTEP16816042.2T patent/LT3380487T/lt unknown
- 2016-11-22 JP JP2018526713A patent/JP6921821B2/ja active Active
- 2016-11-22 EP EP16816042.2A patent/EP3380487B1/en active Active
- 2016-11-22 SM SM20200649T patent/SMT202000649T1/it unknown
-
2020
- 2020-02-21 US US16/797,361 patent/US11213589B2/en active Active
- 2020-11-20 CY CY20201101102T patent/CY1123699T1/el unknown
-
2021
- 2021-07-28 JP JP2021123154A patent/JP7257457B2/ja active Active
- 2021-12-03 US US17/541,636 patent/US20220160883A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220160883A1 (en) | 2022-05-26 |
| US10617765B2 (en) | 2020-04-14 |
| JP2021176890A (ja) | 2021-11-11 |
| US20200276319A1 (en) | 2020-09-03 |
| EP3789395B1 (en) | 2025-08-27 |
| HRP20201832T1 (hr) | 2021-01-08 |
| ES2827776T3 (es) | 2021-05-24 |
| US11213589B2 (en) | 2022-01-04 |
| DK3380487T3 (da) | 2020-12-07 |
| CN115819494A (zh) | 2023-03-21 |
| SI3380487T1 (sl) | 2020-11-30 |
| CN108350025B (zh) | 2023-02-21 |
| EP3789395A1 (en) | 2021-03-10 |
| US20190351065A1 (en) | 2019-11-21 |
| RS61072B1 (sr) | 2020-12-31 |
| JP2019503994A (ja) | 2019-02-14 |
| CN108350025A (zh) | 2018-07-31 |
| KR20180081610A (ko) | 2018-07-16 |
| JP7257457B2 (ja) | 2023-04-13 |
| SMT202000649T1 (it) | 2021-01-05 |
| LT3380487T (lt) | 2020-12-28 |
| EP3380487A1 (en) | 2018-10-03 |
| KR102688003B1 (ko) | 2024-07-23 |
| PT3380487T (pt) | 2020-10-29 |
| HUE052634T2 (hu) | 2021-05-28 |
| PL3380487T3 (pl) | 2020-12-28 |
| WO2017091568A8 (en) | 2018-01-04 |
| JP6921821B2 (ja) | 2021-08-18 |
| WO2017091568A1 (en) | 2017-06-01 |
| EP3380487B1 (en) | 2020-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123699T1 (el) | Συστηματα προσθετων για χρηση σε ρεgυλιωση πρωτεϊνων | |
| CY1123555T1 (el) | Συμπλοκο πρωτεϊνης ιντερλευκινης 15 και χρηση αυτου | |
| EA202090290A1 (ru) | ПРИМЕНЕНИЕ БЕЛКА Cas, СПОСОБ ДЛЯ ОБНАРУЖЕНИЯ ЦЕЛЕВОЙ МОЛЕКУЛЫ НУКЛЕИНОВОЙ КИСЛОТЫ И НАБОР | |
| BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
| BR112018005284A2 (pt) | ácido nucleico interligado guna, método para produzir o mesmo, e composto intermediário | |
| BR112015022119A2 (pt) | Polipeptídeo, composto conjugado, composição farmacêutica, ácido nucleico, vetor, células hospedeiras procariótica e eucariótica, método de produção de um polipeptídeo, e, método de tratamento | |
| EA201490815A1 (ru) | Составы этанерцепта, стабилизированные с помощью аминокислот | |
| MX391646B (es) | Composiciones y métodos para la edición genética eficaz en e. coli usando sistemas de ácido desoxirribonucleico (arn) guía/endonucleasa de sistema asociado a repeticiones palindrómicas cortas agrupadas regularmente espaciadas (cas) en combinación con moldes de modificación de polinucleótido circular. | |
| BR112013014238A2 (pt) | processo para tratar uma formação subterrânea, fluido adequado para uso no processo e sal de amônio da fórmula mx(nh4)yhz-glda ou da fórmula mx(nh4)yhz-mgda | |
| BR112015016580A2 (pt) | composto heterocíclico contendo nitrogênio ou sal deste | |
| PE20130181A1 (es) | Procedimiento para la preparacion de 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridina-2-carboxamida, sus sales y su monohidrato | |
| CY1118883T1 (el) | Μεθοδος παρασκευης βορτιοξετινης | |
| BR112012019561A2 (pt) | hetarilamino naftiridinas | |
| AR098107A1 (es) | Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina | |
| BR112018004447A2 (pt) | derivado de biarila e medicamento contendo o mesmo | |
| BR112015026314A2 (pt) | composto líquido iônico | |
| MX2017006594A (es) | Proteinas y congujados proteinicos con efecto hidrofobo aumentado. | |
| AR095727A1 (es) | Preparación de intermediarios de pirimidina | |
| BR112015024109A2 (pt) | derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp) | |
| EA201590250A1 (ru) | Производные карбамат/мочевины | |
| BR112013001721A2 (pt) | processo de síntese de compostos de ureia substituída | |
| EP2582240A4 (en) | HERBICIDE COMPOSITION BASED ON PICOLINIC ACID SALT | |
| BR112021018733A2 (pt) | Composições de d-metirosina e métodos para preparar as mesmas | |
| BR112015024113A2 (pt) | derivados de uréia e seu uso como inibidores da proteína de ligação de ácido graxo (fabp) | |
| BR112017006193A2 (pt) | método para acoplar um primeiro composto a um segundo composto |